Sunshine Biopharma (SBFM) AI Stock Analysis

• Market Cap: $7.70M
• Dividend Yield: N/A
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.59
• Revenue Growth: 19.22%
• EPS Growth: 98.73%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.39
• Shares Outstanding: 4,555,945
• 10 Day Avg. Volume: 3,175,467
• 30 Day Avg. Volume: 1,091,586
• PEG Ratio: <0.01
• Price to Book (P/B): 0.09
• Price to Sales (P/S): 0.06
• P/FCF Ratio: -0.14
• Enterprise Value/Market Cap: -0.38
• Enterprise Value/Revenue: -0.08
• Enterprise Value/Gross Profit: -0.24
• Enterprise Value/Ebitda: 0.47
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $2.00 ▲(16.28% Upside)

Sunshine Biopharma's stock score is primarily impacted by its financial performance challenges, including profitability and cash flow issues. While technical analysis suggests positive momentum, the negative valuation metrics due to ongoing losses weigh heavily on the overall score. The absence of earnings call insights and corporate events further limits the potential for a higher score.

Sunshine Biopharma Business Overview & Revenue Model

Company Description

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.

How the Company Makes Money

Sunshine Biopharma generates revenue primarily through the development and commercialization of its pharmaceutical products. The company may earn revenue through several key streams, including licensing agreements, partnerships with larger pharmaceutical firms for joint development efforts, and potential sales of its drug candidates upon successful regulatory approval. Additionally, SBFM may seek funding through grants or investments that support its research initiatives. Significant partnerships with research institutions or pharmaceutical companies can also enhance its revenue potential by providing access to additional resources, expertise, and markets.

Sunshine Biopharma Financial Statement Overview

Summary

Sunshine Biopharma is experiencing strong revenue growth but faces significant challenges in achieving profitability. The balance sheet is stable with low leverage, but negative returns on equity highlight ongoing financial struggles. Cash flow issues persist, with negative operating and free cash flows, indicating liquidity concerns. Overall, while growth prospects are promising, the company needs to address profitability and cash flow management to improve its financial health.

Income Statement

Sunshine Biopharma has shown significant revenue growth in recent periods, particularly with a 29.6% increase in TTM. However, the company is struggling with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin is stable but not sufficient to cover operating expenses, leading to consistent net losses.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is reasonable, suggesting a stable asset base relative to equity.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, with a declining trend in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow challenges. Despite this, the free cash flow to net income ratio suggests some alignment between cash flow and reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	36.34M	34.87M	24.09M	4.35M	228.43K	71.41K
Gross Profit	12.11M	10.67M	8.34M	1.70M	110.60K	45.56K
EBITDA	-6.19M	-5.15M	-3.82M	-26.45M	-12.10M	-2.60M
Net Income	-6.31M	-5.13M	-4.51M	-26.74M	-12.44M	-2.78M
Balance Sheet
Total Assets	31.97M	30.56M	27.35M	29.24M	2.20M	1.05M
Cash, Cash Equivalents and Short-Term Investments	10.31M	9.69M	16.29M	21.83M	2.05M	989.89K
Total Debt	929.03K	952.48K	657.71K	4.27M	1.90M	1.91M
Total Liabilities	6.28M	7.06M	6.14M	7.62M	1.99M	2.00M
Stockholders Equity	25.68M	23.50M	21.21M	21.63M	211.66K	-954.84K
Cash Flow
Free Cash Flow	-9.47M	-14.85M	-9.56M	-5.55M	-1.83M	-658.49K
Operating Cash Flow	-7.76M	-12.53M	-8.78M	-5.25M	-1.83M	-657.30K
Investing Cash Flow	-1.78M	-2.32M	-656.15K	-14.62M	0.00	-1.19K
Financing Cash Flow	7.87M	9.29M	3.43M	39.47M	2.90M	1.61M

Sunshine Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBFM, the sentiment is Negative. The current price of 1.72 is below the 20-day moving average (MA) of 1.84, above the 50-day MA of 1.64, and below the 200-day MA of 1.72, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 48.12 is Neutral, neither overbought nor oversold. The STOCH value of 28.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SBFM.

Sunshine Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SBFM	50 Neutral	$7.70M	-0.65	-25.65%	―	19.22%	98.73%
SNOA	47 Neutral	$6.20M	-1.53	-76.14%	―	25.02%	55.11%
EVOK	46 Neutral	$16.61M	-3.72	-152.92%	―	70.02%	82.33%
YCBD	40 Underperform	$7.21M	-0.13	-33.13%	―	-7.80%	90.17%
IMCC	38 Underperform	$6.72M	-2.36	-36.94%	―	2.17%	88.34%
SHPH	32 Underperform	$2.86M	―	-551.04%	―	―	31.53%